OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
DFIR59

DFIR.SI

Food Retail & DistributionVerified

DFIR.SI has a high debt-to-equity ratio of 8.52, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.41, suggesting limited short-term liquidity to cover immediate liabilities. The company's free cash flow of 190.4 million USD is positive, but its operating cash flow of 1.099 billion USD is partially offset by capital expenditures of 148.8 million USD. In terms of profitability, DFIR.SI's return on equity of 84.39% is significantly higher than the typical industry benchmark, indicating strong returns for shareholders. However, its return on assets of 5.05% is relatively modest, suggesting that the company is not efficiently utilizing its assets to generate returns. The company's gross profit of 3.255 billion USD and operating income of 329.5 million USD reflect a healthy margin structure, but the net income of 234.7 million USD is lower than the gross profit, indicating significant operating expenses. DFIR.SI's revenue is concentrated in the Food & Drug Retailing segment, with no disclosed geographic diversification. The company's total revenue of 8.869 billion USD is derived from a single business line, which may expose it to higher operational and market risks. The lack of geographic diversification could limit the company's ability to mitigate regional economic downturns or supply chain disruptions. Looking ahead, DFIR.SI is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the current or next fiscal year. The company's capital expenditures are expected to remain consistent, supporting ongoing operations rather than expansion. The company's free cash flow is expected to remain positive, but the high debt load may constrain future investment opportunities. The company's risk profile is characterized by medium liquidity risk and low dilution potential. The key risk flag is the negative net cash position after subtracting total debt, which could impact the company's ability to meet long-term obligations. The company's debt-to-equity ratio of 8.52 is significantly higher than the industry median, indicating a higher financial leverage risk. The company has not issued additional shares recently, and there is no indication of near-term dilution pressure. Recent events and filings indicate that DFIR.SI has maintained a stable financial position, with no major disruptions or regulatory issues reported. The company's analyst estimates suggest a mean price target of 5.11 USD, with a median of 5.03 USD, indicating a generally positive outlook from the investment community. The mean recommendation of 1.89 suggests a slight bias toward buy ratings, with 2 strong-buy and 6 buy recommendations.

30-day price · DFIR-0.23 (-5.5%)
Low$3.94High$4.38Close$3.96As of28 May, 00:00 UTC
Profile
CompanyDFIR.SI
TickerDFIR.SI
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryFood Retail & Distribution
AI analysis

Business. DFIR.SI operates in the Food Retail & Distribution industry, generating revenue primarily through the sale of food and drug products to consumers.

Classification. DFIR.SI is classified under the industry Food Retail & Distribution within the Consumer Non-Cyclicals economic sector, with a confidence level of 0.92.

DFIR.SI has a high debt-to-equity ratio of 8.52, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.41, suggesting limited short-term liquidity to cover immediate liabilities. The company's free cash flow of 190.4 million USD is positive, but its operating cash flow of 1.099 billion USD is partially offset by capital expenditures of 148.8 million USD. In terms of profitability, DFIR.SI's return on equity of 84.39% is significantly higher than the typical industry benchmark, indicating strong returns for shareholders. However, its return on assets of 5.05% is relatively modest, suggesting that the company is not efficiently utilizing its assets to generate returns. The company's gross profit of 3.255 billion USD and operating income of 329.5 million USD reflect a healthy margin structure, but the net income of 234.7 million USD is lower than the gross profit, indicating significant operating expenses. DFIR.SI's revenue is concentrated in the Food & Drug Retailing segment, with no disclosed geographic diversification. The company's total revenue of 8.869 billion USD is derived from a single business line, which may expose it to higher operational and market risks. The lack of geographic diversification could limit the company's ability to mitigate regional economic downturns or supply chain disruptions. Looking ahead, DFIR.SI is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the current or next fiscal year. The company's capital expenditures are expected to remain consistent, supporting ongoing operations rather than expansion. The company's free cash flow is expected to remain positive, but the high debt load may constrain future investment opportunities. The company's risk profile is characterized by medium liquidity risk and low dilution potential. The key risk flag is the negative net cash position after subtracting total debt, which could impact the company's ability to meet long-term obligations. The company's debt-to-equity ratio of 8.52 is significantly higher than the industry median, indicating a higher financial leverage risk. The company has not issued additional shares recently, and there is no indication of near-term dilution pressure. Recent events and filings indicate that DFIR.SI has maintained a stable financial position, with no major disruptions or regulatory issues reported. The company's analyst estimates suggest a mean price target of 5.11 USD, with a median of 5.03 USD, indicating a generally positive outlook from the investment community. The mean recommendation of 1.89 suggests a slight bias toward buy ratings, with 2 strong-buy and 6 buy recommendations.
Key takeaways
  • DFIR.SI has a high debt-to-equity ratio of 8.52, indicating a capital structure heavily reliant on debt financing.
  • The company's return on equity of 84.39% is significantly higher than the typical industry benchmark, indicating strong returns for shareholders.
  • DFIR.SI's revenue is concentrated in the Food & Drug Retailing segment, with no disclosed geographic diversification.
  • The company's risk profile is characterized by medium liquidity risk and low dilution potential.
  • Analyst estimates suggest a generally positive outlook, with a mean price target of 5.11 USD and a mean recommendation of 1.89.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "DFIR.SI's gross profit margin is expected to remain stable, supported by consistent pricing and cost management strategies.",
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$8.87B
Gross profit$3.25B
Operating income$329.5M
Net income$234.7M
R&D
SG&A
D&A
SBC
Operating cash flow$1.10B
CapEx-$148.8M
Free cash flow$190.4M
Total assets$4.65B
Total liabilities$4.37B
Total equity$278.1M
Cash & equivalents
Long-term debt$2.37B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$278.1M
Net cash-$2.37B
Current ratio0.4
Debt/Equity8.5
ROA5.1%
ROE84.4%
Cash conversion4.7%
CapEx/Revenue-1.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
MetricDFIRActivity
Op margin3.7%3.1% medp25 1.2% · p75 6.8%above median
Net margin2.6%2.0% medp25 0.7% · p75 4.1%above median
Gross margin36.7%26.1% medp25 17.2% · p75 32.0%top quartile
CapEx / revenue-1.7%-2.5% medp25 -4.6% · p75 -1.4%above median
Debt / equity852.0%56.0% medp25 16.8% · p75 121.1%top quartile
Observations
IR observations
Mean price target5.11 USD
Median price target5.03 USD
High price target5.70 USD
Low price target4.30 USD
Mean recommendation1.89 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count6.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.21 USD
Last actual EPS0.12 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 22:37 UTC#63636d5b
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 18:31 UTCJob: 638bd2c6